Biogen will discontinue its controversial Alzheimer's disease drug aducanumab (Aduhelm), the company announcedopens in a new tab or window Wednesday.
The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal antibody that received FDA accelerated approvalopens in a new tab or window in 2021. Biogen also will terminate the confirmatory ENVISION trial, which was a requirement of the drug's accelerated approval.
The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal antibody that received FDA accelerated approvalopens in a new tab or window in 2021. Biogen also will terminate the confirmatory ENVISION trial, which was a requirement of the drug's accelerated approval.
Controversial Alzheimer's Drug Abandoned
Biogen will stop developing and selling aducanumab
www.medpagetoday.com